Platinum-based doublet chemotherapy

DRUG4 trials

Sponsors

Regeneron Pharmaceuticals, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., Suzhou Suncadia Biopharmaceuticals Co., Ltd., The First Hospital of Hebei Medical University

Conditions

Advanced Solid TumorsNon Small Cell Lung CancerNon-small Cell Lung Cancer (NSCLC)Ovarian Cancer

Phase 1

A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers

RecruitingNCT04626635

Regeneron PharmaceuticalsAdvanced Solid Tumors

Start: 2020-12-21End: 2027-04-07Target: 933Updated: 2026-02-02

Phase 2

A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer

Not yet recruitingNCT06211023

Suzhou Suncadia Biopharmaceuticals Co., Ltd.Ovarian Cancer

Start: 2024-02-15End: 2026-06-15Target: 520Updated: 2024-01-18

Phase 4

Jinfukang Oral Liquid Combined With Chemotherapy for Treating Driver Gene-negative Advanced NSCLC

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.Non Small Cell Lung Cancer

Start: 2021-10-25End: 2024-08-15Target: 328Updated: 2021-10-29

Unknown Phase

Efficacy of Argon-Helium Cryoablation Plus PD-1 Inhibitors in NSCLC

CompletedNCT07053215

The First Hospital of Hebei Medical UniversityNon-small Cell Lung Cancer (NSCLC)

Start: 2020-12-01End: 2024-12-01Updated: 2025-07-08

Related Papers

A randomized study of neoadjuvant REGN7075 + cemiplimab + chemotherapy (chemo) vs cemiplimab + chemo in patients (pts) with resectable non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology2025-05-28

A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results.

Journal of Clinical Oncology2024-06-017 citations

A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors, including colorectal cancer: Trial in progress update.

Journal of Clinical Oncology2024-01-20

A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors: Trial-in-progress update.

Journal of Clinical Oncology2023-01-245 citations

735 A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors: initial dose-escalation results

Regular and Young Investigator Award Abstracts2022-11-013 citations

535 A phase I/II study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti–PD-1) in patients with advanced solid tumors

Regular and Young Investigator Award Abstracts2021-11-014 citations